Eli Lilly and Company

Lili Guo

Jorge Alsina-Fernandez

Hongchang Qu

John Lee

Tamer Coskun

Samantha Grace Lyons Keyser

Andrea Renee Geiser

William Christopher Roell

John Philip Mayer

Robert Chadwick Cummins

Daniel Anthony Briere

Milata Mary Abraham

Krister Bengt Bokvist

Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.

Incretin analogs and uses thereof

The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

Long acting amylin receptor agonists and uses thereof

The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus ('T2DM'). Also, the compounds may be useful in the treatment of obesity.

GIPR-agonist compounds

The present invention provides a compound or a pharmaceutically acceptable salt of the Formula:XIVXSLDVPIGLLQILXEQEKQEKEKQQAK*TNAXILAQV-NH

Fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

A peptide compound useful in the treatment of hypoglycemia is described.

Peptide compound for treatment of severe hypoglycemia

The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.

Growing community of inventors

Carmel, IN, United States of America

Lili Guo